Wollastonite

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581156

CAS#: 13983-17-0

Description: Wollastonite is an industrial mineral comprised chemically of calcium, silicon and oxygen. It has been determined to have low biopersistence in both in vivo and in vitro studies, which probably accounts for its relative lack of toxicity. Earlier morbidity studies of mining/mineral processing facilities indicated that exposure to wollastonite might result in pleural plaques (Finland) or decrements in certain measures of lung function (New York). More recent analysis of data from an ongoing health surveillance program at one facility (New York) indicates that there are no pleural plaques or interstitial lung disease or decrements in lung function among never smokers or former smokers occupationally exposed to wollastonite. This result probably reflects continued reduction in exposures as part of an ongoing product stewardship program at this facility and suggests that wollastonite has relatively low toxicity as currently managed.

Chemical Structure

img
Wollastonite
CAS# 13983-17-0
Instruction

Theoretical Analysis

MedKoo Cat#: 581156
Name: Wollastonite
CAS#: 13983-17-0
Chemical Formula: CaHO3Si
Exact Mass: 116.93
Molecular Weight: 117.170
Elemental Analysis: Ca, 34.21; H, 0.86; O, 40.96; Si, 23.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Wollastonite; Wollastonite (Ca(SiO3));

IUPAC/Chemical Name: calcium oxo-l5-silanebis(olate)

InChi Key: WOKUAWKXRJDTAX-UHFFFAOYSA-N

InChi Code: InChI=1S/Ca.HO3Si/c;1-4(2)3/h;4H/q+2;-2

SMILES Code: [SiH](=O)([O-])[O-].[Ca+2]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 117.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Maxim LD, Niebo R, Utell MJ, McConnell EE, Larosa S, Segrave AM. Wollastonite toxicity: an update. Inhal Toxicol. 2014 Feb;26(2):95-112. doi: 10.3109/08958378.2013.857372. Review. PubMed PMID: 24495246.

2: Lee JK, Eum S, Kim J, Hwang KH. Fabrication of Wollastonite Coatings on Zirconia by Room Temperature Spray Process. J Nanosci Nanotechnol. 2016 Feb;16(2):1996-9. PubMed PMID: 27433716.

3: Longo RC, Cho K, Brüner P, Welle A, Gerdes A, Thissen P. Carbonation of wollastonite(001) competing hydration: microscopic insights from ion spectroscopy and density functional theory. ACS Appl Mater Interfaces. 2015 Mar 4;7(8):4706-12. doi: 10.1021/am508313g. Epub 2015 Feb 18. PubMed PMID: 25648453.

4: Lakshmi R, Sasikumar S. Influence of needle-like morphology on the bioactivity of nanocrystalline wollastonite--an in vitro study. Int J Nanomedicine. 2015 Oct 1;10 Suppl 1:129-36. doi: 10.2147/IJN.S79986. eCollection 2015. PubMed PMID: 26491314; PubMed Central PMCID: PMC4599603.

5: Saravanan S, Selvamurugan N. Bioactive mesoporous wollastonite particles for bone tissue engineering. J Tissue Eng. 2016 Nov 24;7:2041731416680319. eCollection 2016 Jan-Dec. PubMed PMID: 27928496; PubMed Central PMCID: PMC5131810.

6: Saravanan S, Vimalraj S, Vairamani M, Selvamurugan N. Role of Mesoporous Wollastonite (Calcium Silicate) in Mesenchymal Stem Cell Proliferation and Osteoblast Differentiation: A Cellular and Molecular Study. J Biomed Nanotechnol. 2015 Jul;11(7):1124-38. PubMed PMID: 26307836.

7: de Sena LÁ, de Almeida MS, de Oliveira Fernandes GV, Guerra Bretaña RM, Castro-Silva II, Granjeiro JM, Achete CA. Biocompatibility of wollastonite-poly(N-butyl-2-cyanoacrylate) composites. J Biomed Mater Res B Appl Biomater. 2014 Aug;102(6):1121-9. doi: 10.1002/jbm.b.33093. Epub 2014 Feb 19. PubMed PMID: 24554625.

8: Ismail H, Shamsudin R, Abdul Hamid MA. Effect of autoclaving and sintering on the formation of β-wollastonite. Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:1077-81. doi: 10.1016/j.msec.2015.09.030. Epub 2015 Sep 11. PubMed PMID: 26478406.

9: Saadaldin SA, Rizkalla AS. Synthesis and characterization of wollastonite glass-ceramics for dental implant applications. Dent Mater. 2014 Mar;30(3):364-71. doi: 10.1016/j.dental.2013.12.007. Epub 2014 Jan 17. PubMed PMID: 24444788.

10: Sainitya R, Sriram M, Kalyanaraman V, Dhivya S, Saravanan S, Vairamani M, Sastry TP, Selvamurugan N. Scaffolds containing chitosan/carboxymethyl cellulose/mesoporous wollastonite for bone tissue engineering. Int J Biol Macromol. 2015 Sep;80:481-8. doi: 10.1016/j.ijbiomac.2015.07.016. Epub 2015 Jul 16. PubMed PMID: 26188305.

11: Salek SS, Kleerebezem R, Jonkers HM, Voncken JH, van Loosdrecht MC. Determining the impacts of fermentative bacteria on wollastonite dissolution kinetics. Appl Microbiol Biotechnol. 2013 Mar;97(6):2743-52. doi: 10.1007/s00253-012-4590-2. Epub 2012 Nov 28. PubMed PMID: 23188461.

12: Zhang Q, Nakamoto T, Chen S, Kawazoe N, Lin K, Chang J, Chen G. Collagen/Wollastonite nanowire hybrid scaffolds promoting osteogenic differentiation and angiogenic factor expression of mesenchymal stem cells. J Nanosci Nanotechnol. 2014 Apr;14(4):3221-7. PubMed PMID: 24734758.

13: Li HC, Wang DG, Chen CZ, Weng F, Shi H. Preparation and characterization of laser cladding wollastonite derived bioceramic coating on titanium alloy. Biointerphases. 2015 Sep 25;10(3):031007. doi: 10.1116/1.4929415. PubMed PMID: 26307502.

14: Xie J, Yang X, Shao H, Ye J, He Y, Fu J, Gao C, Gou Z. Simultaneous mechanical property and biodegradation improvement of wollastonite bioceramic through magnesium dilute doping. J Mech Behav Biomed Mater. 2016 Feb;54:60-71. doi: 10.1016/j.jmbbm.2015.09.012. Epub 2015 Sep 21. PubMed PMID: 26426432.

15: Fiocco L, Li S, Bernardo E, Stevens MM, Jones JR. Highly porous polymer-derived wollastonite-hydroxycarbonate apatite ceramics for bone regeneration. Biomed Mater. 2016 Apr 12;11(2):025016. doi: 10.1088/1748-6041/11/2/025016. PubMed PMID: 27066770.

16: Lin CC, Leung KS, Shen P, Chen SF. Elasticity and structure of the compounds in the wollastonite (CaSiO3)-Na 2SiO 3 system: from amorphous to crystalline state. J Mater Sci Mater Med. 2015 Jan;26(1):5361. doi: 10.1007/s10856-014-5361-7. Epub 2015 Jan 15. PubMed PMID: 25589202.

17: Madesh Kumar M, Nagabhushana H, Nagabhushana BM, Suriyamurthy N, Sharma SC, Shivakumara C, Hari Krishna R. Synthesis, characterization and spectroscopic investigation of Cr3+ doped wollastonite nanophosphor. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jul 15;128:403-7. doi: 10.1016/j.saa.2014.02.059. Epub 2014 Feb 27. PubMed PMID: 24682055.

18: Sarayu K, Iyer NR, Annaselvi M, Ramachandra Murthy A. The Micro-mechanism Involved and Wollastonite Signature in the Calcareous Precipitates of Marine Isolates. Appl Biochem Biotechnol. 2016 Mar;178(6):1069-80. doi: 10.1007/s12010-015-1929-z. Epub 2015 Nov 19. PubMed PMID: 26585115.

19: Maxim LD, McConnell EE. A review of the toxicology and epidemiology of wollastonite. Inhal Toxicol. 2005 Aug;17(9):451-66. Review. PubMed PMID: 16020040.

20: Li B, Liu X, Cao C, Dong Y, Ding C. Biological and antibacterial properties of plasma sprayed wollastonite/silver coatings. J Biomed Mater Res B Appl Biomater. 2009 Nov;91(2):596-603. doi: 10.1002/jbm.b.31434. PubMed PMID: 19496150.